The US Food and Drug Administration (FDA) has granted priority review to Daiichi Sankyo and Merck’s biologics license application (BLA) for patritumab deruxtecan, to potentially treat non-small cell lung cancer (NSCLC) in adults.
AbbVie has signed a definitive agreement to acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx) in a deal that is expected to speed up the former’s commercial and clinical presence in the solid tumour segment.
Boehringer Ingelheim has announced the acquisition of Switzerland-based biotech company T3 Pharmaceuticals in a deal valued at up to CHF450m ($509m).
BeiGene has signed an agreement to acquire an exclusive worldwide license to Ensem Therapeutics’ cyclin-dependent kinase 2 (CDK2) inhibitor.
NeoImmuneTech has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug, NT-I7 (efineptakin alfa) (rhIL-7-hyFc), to treat Acute Radiation Syndrome (ARS), an acute illness.
CASI Pharmaceuticals’ partner Juventas Cell Therapy has received market approval from the China National Medical Products Administration (NMPA) for Inaticabtagene Autoleucel (CNCT 19).
Prelude Therapeutics has announced a partnership with AbCellera for first-in-class precision antibody drug conjugates (ADCs) in oncology.
Shorla Oncology has raised $35m in a Series B funding round to progress its oncology product portfolio.
Orano Med and Orbit Discovery have entered into a partnership for the discovery of specific peptide receptor radionuclide therapies against cancer cells and advance new radiopharmaceuticals development.
The US Food and Drug Administration (FDA) has issued additional guidance to Citius Pharmaceuticals on the resubmission of a biologics license application (BLA) for Lymphir (denileukin diftitox) to treat cutaneous T-cell lymphoma (CTCL).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.